Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company
Jonathan I Silverberg; Emma Guttman-Yassky; Diamant Thaçi; Alan D Irvine; Linda Stein Gold; Andrew Blauvelt; Eric L Simpson; Chia-Yu Chu; Zhuqing Liu; Renata Gontijo Lima; Sreekumar G Pillai; Julien Seneschal; ADvocate1 and ADvocate2 Investigators